mild cases: the critical illness rate of subjects at weeks 2;Severe or critical cases: the Changes of PaO2/FiO2 from baseline to day 1; 3; 5 and 24 hours later after the last administration;Safety data of COVID-19 patients treated with ulinastatin were collected;

mild cases: the critical illness rate of subjects at weeks 2;Severe or critical cases: the Changes of PaO2/FiO2 from baseline to day 1; 3; 5 and 24 hours later after the last administration;Safety data of COVID-19 patients treated with ulinastatin were collected;